L 687384 | 95417-67-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: L 687384
• 英文别名: 1-benzylspiro[1,2,3,4-tetrahydronaphthalene-1,4-piperidine]；10-benzyl-3,4-dihydro-2H-spiro[naphthalene-1,40-piperidine]；L-687384；L687384；L-687,384；1-benzylspiro(piperidine-4,1'-tetralin)；1'-benzyl-3,4-dihydro-2H-spiro[naphthalene-1,4'-piperidine]；1'-benzylspiro[2,3-dihydro-1H-naphthalene-4,4'-piperidine]
• CAS: 95417-67-7
• 化学式: C₂₁H₂₅N
• 分子量: 291.436
• InChiKey: MLDCBJPLHBPJET-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  L 687384 在 palladium dihydroxide 甲酸 、 氢气 、 potassium carbonate 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 100.0 ℃ 、344.73 kPa 条件下， 反应 19.0h， 生成 1'-(pyridin-2-ylmethyl)spiro[2,3-dihydro-1H-naphthalene-4,4'-piperidine]
  参考文献：
  名称：

  Spiropiperidines as high-affinity, selective .sigma. ligands.

  摘要：

  A variety of achiral conformationally restricted spirocyclic piperidines have been prepared in an attempt to investigate the functional role of the central sigma-recognition site. All the compounds possessed a lipophilic N-substituent incorporating either a tetralin, indan, or benzocycloheptane skeleton. Their in vitro affinity at the sigma-site was assessed in radioligand displacement experiments with guinea pig cerebellum homogenates using the sigma-specific radioligand [H-3]-N,N'-di-o-tolyguanidine ([H-3]-DTG, [H-3]-6). A study of the structure-activity relationships identified the N-butyl and N-dimethylallyl substituents as the optimum groups for high affinity and selectivity at the sigma-site (e.g., 3,4-dihydro-1'-(3-methylbut-2-enyl)spiro[1H-indene-1,4'-piperidine] (48), pIC50 = 8.9 vs [3H]-6 and greater than 10000-fold selective over the dopamine D2 receptor). Such compounds are amongst the highest affinity sigma-ligands reported to date, with excellent selectivity over the dopamine D2 receptor, and may serve as at useful tool for exploring the physiological role of the sigma-site.

  DOI：

  10.1021/jm00089a013
• 作为产物：
  描述：

  N,N-双(2-氯乙基)苯甲胺 在 氢氧化钾 、 potassium tert-butylate 、 一水合肼 作用下， 以 二甲基亚砜 、 叔丁醇 、 二乙二醇 为溶剂， 反应 7.0h， 生成 L 687384
  参考文献：
  名称：

  Spiropiperidines as high-affinity, selective .sigma. ligands.

  摘要：

  A variety of achiral conformationally restricted spirocyclic piperidines have been prepared in an attempt to investigate the functional role of the central sigma-recognition site. All the compounds possessed a lipophilic N-substituent incorporating either a tetralin, indan, or benzocycloheptane skeleton. Their in vitro affinity at the sigma-site was assessed in radioligand displacement experiments with guinea pig cerebellum homogenates using the sigma-specific radioligand [H-3]-N,N'-di-o-tolyguanidine ([H-3]-DTG, [H-3]-6). A study of the structure-activity relationships identified the N-butyl and N-dimethylallyl substituents as the optimum groups for high affinity and selectivity at the sigma-site (e.g., 3,4-dihydro-1'-(3-methylbut-2-enyl)spiro[1H-indene-1,4'-piperidine] (48), pIC50 = 8.9 vs [3H]-6 and greater than 10000-fold selective over the dopamine D2 receptor). Such compounds are amongst the highest affinity sigma-ligands reported to date, with excellent selectivity over the dopamine D2 receptor, and may serve as at useful tool for exploring the physiological role of the sigma-site.

  DOI：

  10.1021/jm00089a013

文献信息

• Iron-Catalyzed Oxyfunctionalization of Aliphatic Amines at Remote Benzylic C–H Sites
  作者：Curren T. Mbofana、Eugene Chong、James Lawniczak、Melanie S. Sanford

  DOI：10.1021/acs.orglett.6b02003

  日期：2016.9.2

  iron-catalyzed method for the selective oxyfunctionalization of benzylic C(sp3)–H bonds in aliphatic amine substrates. This transformation is selective for benzylic C–H bonds that are remote (i.e., at least three carbons) from the amine functional group. High site selectivity is achieved by in situ protonation of the amine with trifluoroacetic acid, which deactivates more traditionally reactive C–H sites that are

  我们报告了一种铁催化方法的发展，该方法用于在脂肪族胺底物中的苄基C（sp 3）-H键进行选择性的氧官能化。对于远离胺官能团（至少三个碳原子）的苄基CH键，该转化过程具有选择性。通过用三氟乙酸对胺进行原位质子化，可实现较高的位点选择性，从而使更传统的反应性C–H位（即α至氮原子）失活。通过多种含胺的生物活性分子的合成和衍生化，证明了该方法的范围和合成实用性。
• Synthesis and structure-activity relationship of spiro(isochromanpiperidine) analogs for inhibition of histamine release. IV.
  作者：KUNIKO HASHIGAKI、KIWAMU HIRAMATSU、MASATOSHI YAMATO、KENJI TASAKA

  DOI：10.1248/cpb.32.3561

  日期：——

  Various 1'-(o, m, and/or p-substituted benzyl) (5), 1'-(heterocyclic arylmethyl) (6), and 1'-acyl (7) analogs of spiro [isochroman-3, 4'-piperidin]-1-one were prepared and tested for inhibitory activity on the compound 48/80-induced release of histamine from mast cells. The biological results suggested that the activity is mainly affected by the lipophilicity rather than by the electrostatic character of the 1'-substituent. 4-Benzylspiro [cyclohexane-1, 3'-hexahydroisochroman]-1'-one (17) and 9-benzyl-1-oxaspiro [5.5] undecan-2-one (18) were prepared and found to be inactive, implying that the benzene moiety in the isochroman ring is essential for the activity.

  制备了多种 1'-（邻、间和/或对取代的苄基）(5)、1'-（杂环芳甲基）(6) 和 1'-酰基 (7) 的螺[异苯并吡喃-3, 4'-哌啶]-1-酮类似物，并测试了这些类似物对化合物 48/80 诱导的肥大细胞释放组胺的抑制活性。生物学结果表明，其活性主要受亲脂性而非 1'- 取代基的静电特性的影响。制备了 4-苄螺[环己烷-1，3'-六氢异苯并吡喃]-1'-酮（17）和 9-苄基-1-氧杂螺[5.5]十一烷-2-酮（18），发现它们没有活性，这意味着异苯并吡喃环中的苯分子对活性至关重要。
• Sigma receptor compounds
  申请人：LABORATORIOS DEL DR. ESTEVE, S.A.

  公开号：EP1829862A1

  公开（公告）日：2007-09-05

  The present invention relates to compounds of formula (I), methods for their preparation, medicaments comprising these compounds as well their use in the manufacture of a medicament for the treatment of humans and animals.

  本发明涉及式(I)化合物、其制备方法、包含这些化合物的药物以及它们在制造用于治疗人类和动物的药物中的应用。
• Sigma ligands for use in the prevention and/or treatment of postoperative pain
  申请人：Laboratorios del. Dr. Esteve, S.A.

  公开号：EP2353598A1

  公开（公告）日：2011-08-10

  The invention refers to the use of a sigma ligand, particularly a sigma ligand of formulae (I), (II) or (III) to prevent and/or treat acute and chronic pain developed as a consequence of surgery, especially superficial and/or deep pain secondary to surgical tissue injury, and peripheral neuropathic pain, neuralgia, allodynia, causalgia, hyperalgesia, hyperesthesia, hyperpathia, neuritis or neuropathy secondary to surgical procedure.

  本发明涉及使用sigma配体，特别是公式（I），（II）或（III）的sigma配体，以预防和/或治疗由手术引起的急性和慢性疼痛，特别是手术组织损伤引起的表浅和/或深层疼痛，以及周围神经病理性疼痛，神经痛，触痛，烧伤性痛，痛觉过敏，疼痛过敏，神经炎或手术过程引起的神经病变。
• Piperidine derivatives
  申请人：H. LUNDBECK A/S

  公开号：EP0518805A1

  公开（公告）日：1992-12-16

  Piperidine compounds having the general general Formula I wherein R¹ is a) a group consisting of alkyl, alkenyl, cycloalkyl, cycloalkenyl, phenyl, cycloalkylalkyl, cycloalkenylalkyl, phenylalkyl or diphenylalkyl linked to the piperidyl N-atom through an at least 2 membered spacer group or; b) a group having the general Formula II : wherein X is CHR¹⁰, O, S, SO, SO₂ or NR¹⁰, R¹⁰ being hydrogen, alkyl or alkenyl, an amino group, sulfonyl, optionally substituted phenyl or a hetero aromatic group; Y is CH, CH₂, NH, C=O or C=S; Ra - Rd are substituents; U is CH₂, O or S; Q¹ is a bond , alkylene or alkenylen and Q² alkylene having at least two C-atoms or alkenylene R² and R³ are hydrogen, or alkyl or they may together form an ethylene or propylene bridge; R⁴ to R⁷ are substituents; and i) Z¹ and Z² are linked together in which case: Z¹ is CH₂, O or S; Z² and Z³ are independently (CH₂)n, n being 0 or 1, O or S or Z¹ and Z² may together represent a group -CH=CH-; or when Z³ is (CH₂)n wherein n is 0, Z¹ and Z² may together represent a 3-membered divalent group; or ii) when R¹ is a group as defined in b) Z¹ and Z² may also be unlinked, in which case: Z¹ is substituent, Z² is hydrogen and Z³ is (CH₂)n wherein n is 0; show potent sigma receptor activity. Furthermore they show effect in animal models indicative of anxiolytic properties. Accordingly they are useful as medicines for the treatment of anxiety, psychosis, epilepsy, convulsion, movement disorders, motor disturbances, amnesia, cerebrovascular diseases, senile dementia of the Alzheimer type or Parkinson's disease.

  具有一般式I的哌啶化合物，其中R¹是a)由至少2个成员的间隔基团连接到哌啶N原子的烷基，烯基，环烷基，环烯基，苯基，环烷基烷基，环烯基烷基，苯基烷基或二苯基烷基的群；或b)具有一般式II的群：其中X是CHR¹⁰，O，S，SO，SO₂或NR¹⁰，R¹⁰为氢，烷基或烯基，氨基，磺酰基，可选取代的苯基或杂环芳基；Y是CH，CH₂，NH，C=O或C=S；Ra至Rd是取代基；U是CH₂，O或S；Q¹是键，烷基或烯基，Q²是至少有两个C原子的烷基或烯基，R²和R³是氢，或烷基，或它们可以一起形成乙烯或丙烯桥；R⁴到R⁷是取代基；i）Z¹和Z²连接在一起的情况下：Z¹是CH₂，O或S；Z²和Z³是独立的（CH₂）n，n为0或1，O或S，或Z¹和Z²可以一起表示一个组-CH=CH-；或者当Z³为（CH₂）n，其中n为0时，Z¹和Z²可以一起表示一个3成员双价基团；或ii）当R¹是b）中定义的群时，Z¹和Z²也可以未连接，在这种情况下：Z¹是取代基，Z²是氢，Z³是（CH₂）n，其中n为0；具有强大的sigma受体活性。此外，它们在动物模型中表现出具有抗焦虑特性的效果。因此，它们可用作治疗焦虑症，精神病，癫痫，惊厥，运动障碍，记忆障碍，脑血管疾病，阿尔茨海默病或帕金森病的药物。